Home › Linfoma non Hodgkin › Massachusetts › Boston
Studi clinici su Linfoma non Hodgkin a Boston, MA
26 studi su Linfoma non Hodgkin cercano partecipanti presso sedi a Boston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
In reclutamentoFase 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
In reclutamentoFase 1/2
- Research Site, Boston
- Research Site, Boston
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
In reclutamentoFase 1/2
- Dana-Farber Cancer Institute, Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
In reclutamentoFase 2
- Boston Medical Center, Boston
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
In reclutamentoFase 2
- Dana-Farber Cancer Institute, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
In reclutamentoFase 1
- Tufts Medical Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
In reclutamentoFase 1/2
- Dana-Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
In reclutamentoFase 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
In reclutamentoStudio osservazionale
- Dana Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
In reclutamentoFase 1Volontari sani benvenuti
- Brigham and Women's Hospital, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
In reclutamentoFase 2
- Dana Farber Cancer Institute, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
In reclutamentoStudio osservazionale
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
In reclutamentoFase 1
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
In reclutamentoStudio osservazionale
- Dana-Farber Cancer Institute, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
In reclutamento
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
In reclutamentoFase 2
- Beth Israel Deaconess Medical Center, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
In reclutamentoFase 2Volontari sani benvenuti
- DFCI/BWH Brigham and Women's Hospital, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
In reclutamentoFase 4
- Dana-Farber Cancer Institute, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
In reclutamentoFase 4
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
In reclutamentoFase 1
- Beth Israel Deaconess Medical Center, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
In reclutamentoFase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Studi su Linfoma non Hodgkin in altre città
- New York City, NY31 studi
- Houston, TX31 studi
- Nashville, TN21 studi
- Philadelphia, PA20 studi
- Baldwin Park, CA19 studi
- Washington, DC18 studi
- Chicago, IL18 studi
- Atlanta, GA18 studi
- Milwaukee, WI18 studi
- Columbus, OH18 studi
- Dallas, TX17 studi
- Seattle, WA16 studi
Altri studi a Boston
- Cancro al seno112 studi
- Cancro del polmone non a piccole cellule90 studi
- Cancro (tutti i tipi)85 studi
- Cancro metastatico63 studi
- Cancro colorettale63 studi
- Cancro ai polmoni62 studi
- Cancro ovarico61 studi
- Cancro alla prostata59 studi
- Depressione52 studi
- Cancro dell'endometrio50 studi
- Insufficienza cardiaca44 studi
- Leucemia mieloide acuta44 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.